Stocktoria
Vericel Corp VCEL
Vericel Corp (VCEL) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $276.3M at a 6.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.406 |
| Retained earnings / assets | -0.771 |
| EBIT / assets | 0.023 |
| Equity / liabilities | 2.66 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VCEL | Vericel Corp | 7/9 | 3.1 | 118.9 | +16.5% |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | 2/9 | -7.27 | — | +60.6% |
| VXRT | Vaxart, Inc. | 5/9 | -4.73 | 8.3 | +726.7% |
| ADAPY | Adaptimmune Therapeutics PLC | 3/9 | -13.03 | — | +195.3% |
| TWST | Twist Bioscience Corp | 3/9 | -2.72 | — | +20.3% |
| RGNX | REGENXBIO Inc. | 3/9 | -7.82 | — | +104.5% |
| KRYS | Krystal Biotech, Inc. | 5/9 | 16.61 | 53.6 | +33.9% |
About Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
FAQ
Is VCEL financially healthy?
Vericel Corp's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does VCEL pay a dividend?
No, Vericel Corp does not currently pay a dividend.
How profitable is VCEL?
In FY2025, Vericel Corp had a net margin of 6.0% and a return on equity of 4.7%.
What is VCEL's P/E ratio?
Vericel Corp's trailing price-to-earnings (P/E) ratio is about 118.9×, based on its latest annual earnings.
What is the analyst price target for VCEL?
The average Wall-Street price target for Vericel Corp is $55.43, about 23.9% above the recent price, from 7 analysts.
Is VCEL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Vericel Corp: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 118.9×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.